Lantheus Medical Imaging lands U.S., Canadian supplier approval

By Mass High Tech staff

Video Gallery

MHT's Rodney Brown: App developers see opportunity in new iPhone

MHT's Marc Songini: Researchers focus on macular degeneration

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

Hologic, Conceptus both file appeals in patent case [February 9, 2012]

Personal genomes hold eventual promise for treatments [February 9, 2012]

Pressure BioSciences closes $800,000 offering [February 8, 2012]

Physicians Interactive granted drug tech patents [February 7, 2012]

Diagnostic imaging firm Lantheus Medical Imaging Inc. has received regulatory approval in the U.S. and Canada to use the Australian Nuclear Science and Technology Orgnization (ANSTO) as a supplier of a molecular isotope for the two countries.

Lantheus filed a New Drug Application form with the U.S. Food and Drug Administration and a Supplemental New Drug Submission form with Health Canada.

The isotope, low-enriched uranium-derived molybdenum-99 (Mo-99), derives medical radioisotope technetium-99m (Tc-99m) from it for nuclear diagnostic imaging procedures.

Lantheus uses Tc-99m in its generator line, TechneLite. The company also develops Cardiolite and Definity Vial for Injectable Suspension.

Lantheus said it employs 600 workers at operations in North Billerica, Canada, Puerto Rico and Australia.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.